Phase II trial of paclitaxel and carbopiatin in the treatment of advanced urotherlial carcinoma

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1844-1848

  Redman, Bruce G ^a   Smith, David C ^a   Flaherty, Lawrence ^a   Du, Wei ^a   Hussain, Maha ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; URINARY TRACT CARCINOMA; UROTHELIUM;

EID: 0031803705     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1844     Document Type: Article

References (21)

1. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3:1463-1470, 1985
2. Sternberg SN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
3. Loehrer PJ, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
4. Raabe NK, Fossa SD, Paro G: Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. Br J Urol 64:604-607, 1989
5. Akaza H, Hagiwara M, Deguchi N, et al: Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract. Cancer Chemother Pharmacol 23:181-185, 1989
6. Trump DL, Elson P, Madajewicz S, et al: Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium: The Eastern Cooperative Oncology Group. J Urol 144:1119-1122, 1990
7. Waxman J, Barton C: Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 19:21-25, 1993
8. Petriolli R, Frediani B, Manganelli A, et al: Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. Cancer 77:344-351, 1996
9. Pazdur R, Kudelka AP, Kavanagh JJ, et al: New drugs. The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19:351-386, 1993
10. Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270, 1994
11. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacological study. J Clin Oncol 9:1692-1703, 1991
12. Van Oosterom AT, Akaza H, Hall R, et al: Response criteria phase II/phase III invasive bladder cancer, in Denis L, Niijima T, Prout G, Schroeder FH, (eds): Developments in Bladder Cancer. New York, NY, Liss, 1986, pp 301-310
13. Sternberg CN, Yagoda A, Scher HI, et al: Preliminary results of MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407, 1985
14. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
15. Saxman SB, Propert KJ, Einhorn LH, et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15:2564-2569, 1997
16. Bunn PA: The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin Oncol 23:18-25, 1996 (suppl 6)
17. Huizing MT, van Warmerdam LJ, Rosing H, et al: Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15:1953-1964, 1997
18. Obasaju CK, Johnson SW, Rogatko A, et al: Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Can Res 2:549-552, 1996
19. Huizing MT, Giaccone G, van Warmerdam LJ, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 15:317-329, 1997
20. Schnack B, Grbovic M, Brodowicz T, et al: High effectivity of a combination of Taxol and carboplatin in the treatment of metastatic urothelial cancer. Proc Am Soc Clin Oncol 16:325, 1997 (abstr)
21. Vaughn DJ, Malkowicz SB, Zoltick B, et al: Phase I trial of paclitaxel/carboplatin in advanced carcinoma of the urothelium. Semin Oncol 24:S47-S50, 1997 (suppl 2)